Mainz (dpa) – The German vaccine manufacturer Biontech, which together with Pfizer developed the world’s first approved coronavirus vaccine, made billions in profit once again in 2022 and now intends to further advance the development of therapies to treat conditions such as cancer. To fight infectious and autoimmune diseases and cancer, Biontech is researching approaches in immunotherapy based on the molecule messenger RNA. For future oncology products, Biontech wants to set up a sales organisation in the USA, EU and other selected regions in 2023 and 2024. In total, the company is planning to invest 2.4 to 2.6 billion euros in research and development in 2023.
(Except for the headline, this story has not been edited by PostX News and is published from a syndicated feed.)
